Esperion Therapeutics, Inc.

ESPR

CIK 0001434868 · Pharmaceutical Preparations · Nasdaq

← back to feed

Revenue (TTM)

$314.79M

+21.3% YoY Q1 Apr 2026

Net Income (TTM)

−$109.71M

+56.2% YoY Q1 Apr 2026

EPS Diluted (TTM)

−$0.53

+60.7% YoY Q1 Apr 2026

Gross Margin

—

Q1 Apr 2026

Operating Margin

-10.0%

Q1 Apr 2026

Net Margin

-34.9%

Q1 Apr 2026

Free Cash Flow (TTM)

−$51.14M

Q1 Apr 2026

Cash

$156.16M

Q1 Apr 2026

Total Debt

$292K

Q1 Apr 2026

Shares Outstanding

257.43M sh

Q1 Apr 2026

Recent filings

8-K/A Material Event

Jun 18, 2026 details → sec.gov ↗

8-K Material Event

Jun 16, 2026 details → sec.gov ↗